Gene News

Ontario – Toronto GTA – Richmond Hill


Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0




ChondroGene is an applied genomics company focussed on
developing novel diagnostics and therapeutics for human
osteoarthritis (OA). The Company has 11 scientific staff and
carries out research at its facilities in Toronto.
ChondroGene€™s parent company, ChondroGene Limited, is a publicly
held company listed on the TSX Venture Exchange under the stock
symbol YDG.
Country of Ownership: Canada
Year Established: 1998
Exporting: No
Primary Industry (NAICS): 541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity: Services
Number of Employees: 13

Genomic research

ChondroGene has constructed cDNA libraries from patient samples
representing fetal, normal and various stages of OA disease
progression. Characterization of the cDNA libraries has
resulted in comprehensive identification of the genes that are
expressed in human cartilage cells in health and disease.
ChondroGene has also designed and constructed the first known
human chondrocyte-specific microarray, the ChondroChipâ„¢, an
important platform technology for the identification and
development of an early OA diagnostic and novel therapeutics.

Plant Information: Total Plant Size (Areas sq ft): 6,200 sq ft
laboratory and
office facility in

No associations


Say what you really think

Search for Canadian companies and directors. Rate them and share your experience with other people.


Gene News does not yet have a rating. At this time, there are no reviews or comments for this company.

If you have personal experience with Gene News, we encourage you to share that experience with our community. Your opinion is very important and Gene News will most certainly appreciate the feedback.

Rate now


Profile ID: LFCA-COD-O-278

All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.